Clinical Trials | A Phase I/II Clinical Trial Evaluating CC-486 in Patients with Relapsed/Refractory T-Cell Large Granular Lymphocytic Leukemia (T-LGLL)
A Phase I/II Clinical Trial Evaluating CC-486 in Patients with Relapsed/Refractory T-Cell Large Granular Lymphocytic Leukemia (T-LGLL)
The University of Virginia is conducting a clinical research study for adults ages 18 and over who have relapsed/ refractory T-Cell Large Granular Lymphocytic Leukemia (T-LGLL). The purpose of the study is to assess the safety and tolerability (how a person’s body reacts) to CC-486 in patients with relapsed and refractory T-LGLL. The other goal of this study is to find the proportion of patients who will respond to CC-486 therapy. CC-486 has been approved by the US Food and Drug Administration for treating adults with acute myeloid leukemia. If you participate in this study, you will take CC-486 by mouth once a day for 14 days in a 28 day cycle for a minimum of 4 cycles. You are expected to be in this research study for a minimum of 4 months. Study-related procedures that are being done beyond your standard of care will be provided at no cost to you or your insurance. Additional information can be found here: https://clinicaltrials.gov/study/NCT05141682 [email protected]